Patent: 9,994,914
✉ Email this page to a colleague
Summary for Patent: 9,994,914
Title: | Mutation in the epidermal growth factor receptor kinase domain |
Abstract: | A new in-frame deletion was found in exon 19 of the EGFR gene, the exon that is often mutated in tumors. The invention comprises methods of detecting the mutation, methods of prognosis and methods of predicting response to treatment based on the presence of absence of the mutation. |
Inventor(s): | Hoglund; Bryan (Pleasanton, CA), Jin; Janet (Foster City, CA), Li; Yan (Palo Alto, CA), Liu; Wei-Min (Dublin, CA) |
Assignee: | Roche Molecular Systems, Inc. (Pleasanton, CA) |
Application Number: | 14/873,931 |
Patent Claims: | see list of patent claims |
Details for Patent 9,994,914
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 02/12/2004 | ⤷ Try a Trial | 2034-10-09 |
Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 03/28/2007 | ⤷ Try a Trial | 2034-10-09 |
Amgen, Inc. | VECTIBIX | panitumumab | Injection | 125147 | 09/27/2006 | ⤷ Try a Trial | 2034-10-09 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |